A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC)
Authors:
- Koichi GotoKGKoichi Goto
- Makoto NishioMNMakoto Nishio
- Noboru YamamotoNYNoboru Yamamoto
- Kenichi ChikamoriKCKenichi Chikamori
- Toyoaki HidaTHToyoaki Hida
- Makoto MaemondoMMMakoto Maemondo
- Nobuyuki KatakamiNKNobuyuki Katakami
- Toshiyuki KozukiTKToshiyuki Kozuki
- Hiroshige YoshiokaHYHiroshige Yoshioka
- Takashi SetoTSTakashi Seto
- Tamaki FukuyamaTFTamaki Fukuyama
- Tomohide TamuraTTTomohide Tamura
Open Access
- 1 October 2013
- journal article
- research article
- Published by Elsevier in Lung Cancer
- Vol. 82 (1) , 109-114
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialThe Lancet Oncology, 2012
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyThe Lancet Oncology, 2011
- Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)Journal of Clinical Oncology, 2011
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFRNew England Journal of Medicine, 2010
- Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 studyThe Lancet Oncology, 2010
- Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trialThe Lancet Oncology, 2010
- Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcomes in Previously Untreated Non–Small Cell Lung Cancer Patients: Results of an Online Tumor Registry of Clinical TrialsClinical Cancer Research, 2009
- Efficacy and Safety of Erlotinib Monotherapy for Japanese Patients with Advanced Non-small Cell Lung Cancer: A Phase II StudyJournal of Thoracic Oncology, 2008
- Detection of Epidermal Growth Factor Receptor Mutations in Serum as a Predictor of the Response to Gefitinib in Patients with Non–Small-Cell Lung CancerClinical Cancer Research, 2006
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2005